Drugs /

enobosarm

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
enobosarm
Trade Name(s):
Osterine
NCI Definition [1]:
A non-steroidal agent with anabolic activity. Selective androgen receptor modulator (SARM) GTx-024 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone's action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.

Clinical Trials

View Clinical Trials for enobosarm

Enobosarm has been investigated in 4 clinical trials, of which 2 are open and 2 are closed. Of the trials investigating enobosarm, 3 are phase 2 (1 open) and 1 is phase 3 (1 open).

AR Expression, AR Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for enobosarm clinical trials.

Breast carcinoma is the most common disease being investigated in enobosarm clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Enobosarm
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Enobosarm
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating enobosarm and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gtx-024, Osterine, gtx 024, selective androgen receptor modulator gtx-024, gtx-024, ostarine, gtx-024, propanamide, 3-(4-cyanophenoxy)-n-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-, (2s)-, enobosarm, ostarine
Drug Categories [2]:
Selective estrogen receptor modulators (SERMs)
NCIT ID [1]:
C69161

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.